Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation

Estrogen receptor alpha (ERα)-positive breast cancers are frequently treated with tamoxifen, but resistance is common. It remains elusive how tamoxifen resistance occurs and predictive biomarkers for treatment outcome are needed. Because most biomarker discovery studies are performed using pre-treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Severson, Tesa M., Nevedomskaya, Ekaterina, Peeters, Justine, Kuilman, Thomas, Krijgsman, Oscar, van Rossum, Annelot, Droog, Marjolein, Kim, Yongsoo, Koornstra, Rutger, Beumer, Inès, Glas, Annuska M., Peeper, Daniel, Wesseling, Jelle, Simon, Iris M., Wessels, Lodewyk, Linn, Sabine C., Zwart, Wilbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085127/
https://www.ncbi.nlm.nih.gov/pubmed/27129152
http://dx.doi.org/10.18632/oncotarget.8983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085127/
https://www.ncbi.nlm.nih.gov/pubmed/27129152
http://dx.doi.org/10.18632/oncotarget.8983

Ejemplares similares